Ultragenyx Pharmaceutical: Q2 Earnings Insights

Shares of Ultragenyx Pharmaceutical RARE moved higher in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 61.61% year over year to ($1.81), which missed the estimate of ($1.36).

Revenue of $86,975,000 higher by 40.94% year over year, which beat the estimate of $85,030,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 02, 2021

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/qkvrta2a

Price Action

Company's 52-week high was at $179.65

Company's 52-week low was at $72.83

Price action over last quarter: down 23.74%

Company Profile

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!